Pressure Ulcer
Conditions
Keywords
non-healing wounds, pressure ulcer, platelet rich plasma
Brief summary
To assess the efficacy of the PRP Concepts Fibrin Bio-Matrix and compare its performance with usual and customary practice for the treatment of chronic non-healing pressure ulcers (PU).
Detailed description
This is a prospective, randomized, single-blind, controlled, multi-center study for subjects undergoing PU treatment. Qualified subjects will be randomized (1:1); test group (PRP Concepts Fibrin Bio-Matrix) and control group (usual and customary practice). The study will consist of 3 periods: a screening period, an active treatment period, and a follow-up period (if healed). Approximately 250 subjects will be enrolled. Subjects will be ≥18 years of age with a PU (greater than 4 weeks duration). Each subject will be enrolled in the active treatment period for up to 12 weeks, or to closure of wound with a confirmatory visit 2 weeks after wound closure, whether such closure occurs at 12 weeks or earlier.
Interventions
Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
Ussual and customary care of non-healing pressure wounds
Sponsors
PRP Concepts, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Medicare/Medicaid eligible Ulcer of pressure/shear etiology The index ulcer is greater than 4 weeks duration. Three or fewer ulcers that are separated by \> 3.0 cm distance The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (Index Ulcer) that is located on the heel, ischium, sacrum, and trochanter Post-debridement, the ulcer size must be between 2 cm2 and 200 cm2 Demonstrated adequate offloading regimen Able and willing to attend scheduled follow-up visits and study related exams Able and willing to provide a voluntary written informed consent
Exclusion criteria
Stage I pressure ulcers Ulcers that are unstageable or of deep tissue morphology that have yet to become an open wound Ulcer not of PU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, venous, or arterial etiology) Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator Gross clinical infection at the study ulcer site including cellulitis and osteomyelitis. Known allergy tor sensitivity to Eclipse PRP kit components (calcium chloride, calcium gluconate or acid citrate dextrose solution A (ACDA)) Serum albumin of less than 2.5 g/dL, Plasma Platelet count of less than 100 x 109/L, Hemoglobin of less than 10.5 g/dL Known renal failure as determined by a Creatinine \> 2.5 mg/dl Malignancy at or near the ulcer site Rheumatoid arthritis (and other collagen vascular disease), vasculitis, sickle cell disease, HIV Severe liver disease. Presence of additional abnormal lab values obtained within 7 days prior to the Day 0 visit determined to be clinically significant by the investigator including: WBC \>13,000/cm3 or \< 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment Received another investigational device or drug within 30 days of enrollment Received allograft, autograft or xenograft within 30 days of enrollment Subject has inadequate venous access for repeated blood draw required for Eclipse RPR administrations Subject requires or is anticipated to require interventions directed at improvement of arterial perfusion to affected area Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT) Presence of another wound that is concurrently treated and might interfere with treatment of index wound Subjects who are cognitively impaired and do not have a healthcare proxy Life expectancy of \< 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of wounds that have healed at 12 weeks | 12 weeks | To assess the efficacy and safety of an autologous PRP membrane matrix treatment by measurement and observation of time to and percent of complete wound closure, wound healing trajectory, and wound recurrence over time as compared to the standard of care non-healing wound treatment. |
| To assess by a validated interview-scoring tool, the changes in quality of life and ability to return to previous function/resumption of normal activities. | 12 weeks | To assess by a validated interview-scoring tool, the changes in quality of life and ability to return to previous function/resumption of normal activities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wound trajectory (Mean Change) | 12 weeks | Mean of percent (%) wound size changes at 4 weeks, 8 weeks and 12 weeks |
| Wound trajectory (Median Change) | 12 weeks | Median of percent (%) wound size changes at 4 weeks, 8 weeks and 12 weeks |
| Ulcer recurrence | 3 months | Ulcer recurrence out to 3 months for subjects whose wounds heal by conclusion of 12 week visit. |
| Quality of Life Health Survey | 3 months | Changes in Quality of Life scores and ability to return to previous function/resumption of normal activities |
Countries
United States
Contacts
Primary ContactDamon Keeley
Backup ContactNigel Gladhart
Outcome results
None listed